# Safety and Efficacy of Sentinel Node Biopsy Omission for Breast Cancer Patients Who Plan to Have Adjuvant Chemotherapy

> **NCT02610621** · PHASE2 · WITHDRAWN · sponsor: **Cedars-Sinai Medical Center**

## Conditions studied

- Breast Cancer

## Interventions

- **PROCEDURE:** Lumpectomy without sentinel node biopsy

## Key facts

- **NCT ID:** NCT02610621
- **Lead sponsor:** Cedars-Sinai Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2015-12
- **Primary completion:** 2017-04
- **Final completion:** 2020-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study may not be clinically relevant at this time.
- **Last updated:** 2016-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02610621

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02610621, "Safety and Efficacy of Sentinel Node Biopsy Omission for Breast Cancer Patients Who Plan to Have Adjuvant Chemotherapy". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT02610621. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*